tiprankstipranks
Trending News
More News >
BioVie (BIVI)
NASDAQ:BIVI
US Market
Advertisement

BioVie (BIVI) Price & Analysis

Compare
541 Followers

BIVI Stock Chart & Stats


BioVie News

BIVI FAQ

What was BioVie’s price range in the past 12 months?
BioVie lowest stock price was $1.42 and its highest was $75.00 in the past 12 months.
    What is BioVie’s market cap?
    BioVie’s market cap is $11.45M.
      When is BioVie’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were BioVie’s earnings last quarter?
      BioVie released its earnings results on Feb 14, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.055.
        Is BioVie overvalued?
        According to Wall Street analysts BioVie’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does BioVie pay dividends?
          BioVie does not currently pay dividends.
          What is BioVie’s EPS estimate?
          BioVie’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does BioVie have?
          BioVie has 7,534,225 shares outstanding.
            What happened to BioVie’s price movement after its last earnings report?
            BioVie reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -0.761%.
              Which hedge fund is a major shareholder of BioVie?
              Among the largest hedge funds holding BioVie’s share is Sheaff Brock Investment Advisors LLC. It holds BioVie’s shares valued at 0.

                Company Description

                BioVie

                BioVie Inc. (BIVI) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver disease, specifically targeting unmet medical needs in the treatment of chronic liver disorders and neurological conditions. The company's core products include NE3107, a novel molecule aimed at treating Alzheimer's and Parkinson's diseases, and BIV201, an innovative treatment for ascites due to liver cirrhosis.

                BioVie (BIVI) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Can-Fite BioPharma
                Lipocine
                Edesa Biotech
                Unity Biotechnology
                Cingulate Inc

                Ownership Overview

                15.10%8.39%0.39%75.78%
                15.10% Insiders
                0.39% Other Institutional Investors
                75.78% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis